ID   IST-MEL1
AC   CVCL_1308
SY   ISTMEL1; Istituto Scientifico Tumori-MELanoma 1
DR   CLO; CLO_0006969
DR   CLDB; cl5539
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-3610
DR   CCLE; ISTMEL1_SKIN
DR   Cell_Model_Passport; SIDM00225
DR   ChEMBL-Cells; CHEMBL3308290
DR   ChEMBL-Targets; CHEMBL2366094
DR   Cosmic; 907172
DR   Cosmic-CLP; 907172
DR   DepMap; ACH-002143
DR   GDSC; 907172
DR   GEO; GSM1669942
DR   IARC_TP53; 21398
DR   ICLC; HTL01006
DR   LINCS_HMS; 50020
DR   LINCS_LDP; LCL-1234
DR   PharmacoDB; ISTMEL1_669_2019
DR   Wikidata; Q54898343
RX   PubMed=20164919;
RX   PubMed=27397505;
RX   PubMed=30894373;
CC   Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC   Part of: COSMIC cell lines project.
CC   Population: Caucasian.
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (CCLE; Cosmic-CLP).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Asn247Lys (c.741C>A); Zygosity=Homozygous (CCLE; Cosmic-CLP).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Homozygous (CCLE; Cosmic-CLP).
CC   Omics: Deep exome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
CC   Genome ancestry: African=1.49%; Native American=1.88%; East Asian, North=0%; East Asian, South=1.65%; South Asian=5.96%; European, North=29.45%; European, South=59.56% (PubMed=30894373).
CC   Derived from sampling site: Skin.
ST   Source(s): Cosmic-CLP; ICLC
ST   Amelogenin: X (Cosmic-CLP)
ST   Amelogenin: X,Y (ICLC)
ST   CSF1PO: 10,12
ST   D13S317: 9,12
ST   D16S539: 11,12
ST   D21S11: 33.2,34.2
ST   D5S818: 11,13
ST   D7S820: 9,10
ST   TH01: 9
ST   TPOX: 8
ST   vWA: 16,18
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens
SX   Male
AG   Adult
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 20-05-21; Version: 24
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M.,
RA   Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M.,
RA   Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A.,
RA   Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//